Kanjinti®
ACTIVE PRINCIPLE:
Trastuzumab
INDICATION:
Breast cancer
Stomach cancer
DATE:
28/05/2018
STATUS:
Authorized
Biosimilar medicine authorized by the AEMPS
ACTIVE PRINCIPLE:
Trastuzumab
INDICATION:
Breast cancer
Stomach cancer
DATE:
28/05/2018
STATUS:
Authorized
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.